HDAC inhibitors are expected to improve this disadvantage of anti-PD-1/PD-L1 antibody treatment through the downregulation of HLA class I during anti-PD-1/PD-L1 antibody treatment against Merkel cell carcinoma [78]. Here, CD274 is linked to Merkel cell skin cancer.